Steffan C. Tomlinson
Analyst · Michael Turits from Raymond James
Thank you, Mark, and thank you, all, for joining us today. I'll first review our results for Q3 '13 and then conclude with our outlook for Q4 '13. In Q3, total revenue grew to $101.3 million, an increase of 54.2% year-over-year and 5% sequentially. Looking at our 2 main components of revenue, in Q3, product revenue of $60.8 million grew 39.7% year-over-year and decreased 1.9% sequentially. The sequential decrease was primarily in Europe and in our federal vertical. Services revenue of $40.5 million, which represented 40% of total revenue, grew 82.6% year-over-year and 17.2% sequentially, driven in part by an increase in the attach rates of our subscription services. This growth in services revenue underscores the power of our hybrid revenue model. The geographic mix of revenue was 62% Americas, 23% EMEA, and 15% APAC, with all theaters posting growth on a year-over-year basis. On a sequential basis, Americas and APAC posted solid growth, while EMEA declined by approximately 4% following 2 quarters of 23% sequential growth for both Q1 '13 and Q2 '13. Total non-GAAP gross margin in Q3 was 74.1%, ahead of our target range of 70% to 73%. Non-GAAP gross margin increased 220 basis points year-over-year and 190 basis points sequentially. Putting a finer point on gross margin, Q3 non-GAAP product gross margin was 74.3%, an increase of 70 basis points year-over-year and 90 basis points sequentially. The sequential increase was primarily due to cost reductions and product mix. Our non-GAAP service gross margin was 73.7%, up 510 basis points year-over-year and up 360 basis points sequentially. The sequential increase was primarily due to increasing services as a percentage of total revenue and higher attach rates for our subscription services, as well as leveraging our customer service organization. Having added over 1,000 end customers in the quarter, we'll continue to invest in customer support and services gross margins will fluctuate depending on the timing of the investment ramp of our service organization. Moving on to operating expenses. Q3 non-GAAP research and development expense was $12.9 million, a decrease of $0.7 million from the prior quarter, due in part to the timing of expenditures related to certain projects. As a percentage of revenue, non-GAAP R&D expense was 12.7%, down 130 basis points sequentially. Q3 non-GAAP sales and marketing expense was $45.6 million, an increase of $3.7 million from the prior quarter, due to the addition of quota carrying headcount and commission-related expenses. As a percentage of revenue, it was 45%, an increase of 160 basis points sequentially. Q3 non-GAAP general and administrative expense was $9.3 million, an increase of $1.5 million from the prior quarter or 9.1% as a percentage of revenue, up 110 basis points sequentially. G&A was impacted by expenses related to setting up our international corporate structure, ERP implementation and litigation costs. In total, Q3 non-GAAP operating expenses were $67.7 million, an increase of $4.6 million from the prior quarter, or 66.8% of revenue, up 140 basis points sequentially. Q3 non-GAAP operating margin was 7.2%, an increase of 40 basis points sequentially. The sequential improvement this quarter can be primarily attributed to the gross margin improvement. As we stated previously, given our leading position in the market and the fact that we're growing revenue at a much higher rate than both the market and our competitors, our goal is to continue to invest while growing operating margin in a slow and steady manner, noting there may be near-term fluctuations in operating margin. Our non-GAAP effective tax rate for this quarter was 38.5%. This rate will continue to fluctuate throughout the fiscal year, as it's dependent on our global pretax profit mix and potential discrete events, such as the removal of our domestic valuation allowance. Non-GAAP net income for Q3 was approximately $4.5 million or $0.06 per diluted share using 78 million shares. And this compares to non-GAAP net income of $3.9 million or $0.05 per diluted share in fiscal Q2 '13, and non-GAAP net income of $4.7 million or $0.07 per diluted share in fiscal Q3 '12. On a GAAP basis, net loss was $7.3 million or $0.10 per basic and diluted share. Turning to the balance sheet. We finished April with cash, cash equivalents and investments of $391.5 million. In Q3, cash flow from operations was $15.2 million, free cash flow was $8.8 million and free cash flow margin was 8.7%. While cash flow from operations and free cash flow were impacted by the quarter's linearity, deferred revenue and billings grew strongly, giving us increased visibility on future cash flows. Capital expenditures in the quarter were within our anticipated range of $5 million to $10 million and totaled $6.4 million. As I mentioned previously, in fiscal 2014, we'll see an increase of approximately $10 million to $12 million in CapEx related to the relocation of our headquarters facility. Most of this increase will be in fiscal Q1 of 2014. The annual operating expense starting in FY '14 for this new facility will be approximately $13 million for the year. We ended Q3 with $91.5 million of accounts receivable, up from the Q2 '13 balance of $68.6 million. The quality of our accounts receivables is excellent. Average days sales outstanding were 71 days, up from 58 days last quarter, reflecting both a back end-loaded quarter and a higher mix of subscription and multiyear deals. Moving down the balance sheet, total deferred revenue was $219.3 million, an increase of 88% year-over-year and 16.5% sequentially. Short-term deferred revenue was $134 million, an increase of 14.1% sequentially. We're continuing to see an uptick in multiyear deals. Billings were $132.4 million, an increase of 56.8% year-over-year and 6.5% sequentially. Let me now turn to our guidance for Q4 '13. We expect revenue to be in the range of $106 million to $110 million, which equates to 40% to 45% year-over-year growth, and we expect non-GAAP EPS to be approximately $0.06 per share using 78 million to 80 million shares on a diluted basis. While we're mindful of the current macroeconomic uncertainty, we're continuing to invest in product development, sales and go-to market functions, as well as discrete projects and G&A and have factored all this into our guidance for Q4. With that, I'll turn the call over to the operator to open the Q&A session.